NASDAQ:TCDA

Tricida Stock Forecast, Price & News

$4.21
+0.01 (+0.24 %)
(As of 07/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.98
$4.23
50-Day Range
$3.66
$5.35
52-Week Range
$3.61
$15.33
Volume213,843 shs
Average Volume441,413 shs
Market Capitalization$211.64 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
30 days | 90 days | 365 days | Advanced Chart
Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.


Tricida logo

About Tricida

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.80 out of 5 stars

Medical Sector

201st out of 2,215 stocks

Pharmaceutical Preparations Industry

93rd out of 867 stocks

Analyst Opinion: 3.1Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tricida (NASDAQ:TCDA) Frequently Asked Questions

Is Tricida a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Tricida stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCDA, but not buy additional shares or sell existing shares.
View analyst ratings for Tricida
or view top-rated stocks.

What stocks does MarketBeat like better than Tricida?

Wall Street analysts have given Tricida a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tricida wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tricida?

Tricida saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 3,280,000 shares, a decline of 21.5% from the June 15th total of 4,180,000 shares. Based on an average daily volume of 363,300 shares, the short-interest ratio is presently 9.0 days. Currently, 8.3% of the company's stock are sold short.
View Tricida's Short Interest
.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Tricida
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) posted its quarterly earnings data on Thursday, May, 6th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.17.
View Tricida's earnings history
.

How has Tricida's stock price been impacted by COVID-19 (Coronavirus)?

Tricida's stock was trading at $28.05 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TCDA shares have decreased by 85.0% and is now trading at $4.21.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for TCDA?

4 equities research analysts have issued 1 year price targets for Tricida's shares. Their forecasts range from $8.00 to $40.00. On average, they expect Tricida's stock price to reach $19.50 in the next twelve months. This suggests a possible upside of 363.2% from the stock's current price.
View analysts' price targets for Tricida
or view top-rated stocks among Wall Street analysts.

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 50, Pay $719.98k)
  • Mr. Geoffrey M. Parker, COO, CFO & Exec. VP (Age 56, Pay $502.33k)
  • Dr. Wilhelm Stahl, Exec. VP & CTO (Age 61, Pay $472.06k)
  • Mr. Robert L. McKague J.D., Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
  • Dr. Dawn Parsell Ph.D., Exec. VP of Clinical Devel. (Age 59, Pay $504.92k)
  • Ms. Annie Yoshiyama, VP of Fin. & Chief Accounting Officer (Age 38)
  • Jackie Cossmon, VP of Investor Relations & Communications
  • Mr. Edward J. Hejlek Esq., J.D., Exec. VP of Intellectual Property (Age 64)
  • Mr. Marc Cobo, Consultant (Age 41)

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida CEO Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among Tricida's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $4.21.

How much money does Tricida make?

Tricida has a market capitalization of $211.64 million. The company earns $-264,790,000.00 in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does Tricida have?

Tricida employs 64 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

Where are Tricida's headquarters?

Tricida is headquartered at 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]


This page was last updated on 7/24/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.